TELA Bio, Inc.
Close on Oct 19, 2026
- Market cap
- $55.71M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 12, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 10, 2026 | After market close | $19.30M | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | Apr 30, 2026 | After market close | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 24, 2026 | After market close | $20.90M | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 13, 2025 | After market close | $20.70M | $-0.19 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 11, 2025 | After market close | $20.20M | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 8, 2025 | After market close | $18.50M | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 20, 2025 | After market close | $17.60M | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Oct 22, 2024 | After market close | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 12, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 9, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 21, 2024 | After market close | – | – | – |
Company guidance
Outlook given with results on Mar 24, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| revenue growth | Full year 2026 | 8% growth | New |
| revenue | First quarter 2026 | $18.50M | New |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements TELA Bio filed with the SEC
510(k) Clearance for Liora TM Monofilament Scaffold for Soft Tissue Reinforcement
Other events · EX-99.1 to Form 8-K
and Strategic Cost Reduction Initiative
Exit or restructuring costs · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
2026 -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue
Results of operations · EX-99.1 to Form 8-K
MALVERN, PA, May 12, 2026 -- TELA Bio, Inc.
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
We provide innovative soft - tissue reconstruction solutions that optimize clinical outcomes by prioritizing the Preservation and Restoration of the patient’s own anatomy. 3 Our Mission
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
EX-99.1 to Form 8-K
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
We provide innovative soft - tissue reconstruction solutions that optimize clinical outcomes by prioritizing the Preservation and Restoration of the patient’s own anatomy. 3 Our Mission
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Third Quarter 2025 Financial Results and Refinancing and Upsizing of Credit Facility
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
We provide innovative soft - tissue reconstruction solutions that optimize clinical outcomes by prioritizing the Preservation and Restoration of the patient’s own anatomy. 3 Our Mission
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
EX-99.1 to Form 8-K
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
We provide innovative soft - tissue reconstruction solutions that optimize clinical outcomes by prioritizing the Preservation and Restoration of the patient’s own anatomy. 3 Our Mission
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Company Further Strengthens Executive Leadership
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
MALVERN, PA, May 8, 2025 -- TELA
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
We provide innovative soft - tissue reconstruction solutions that optimize clinical outcomes by prioritizing the Preservation and Restoration of the patient’s own anatomy. 3 Our Mission
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
PRS for Plastic and Reconstructive Surgery
Other events · EX-99.1 to Form 8-K
PA, March 20, 2025 -- TELA Bio, Inc. ("TELA Bio"),
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
We provide innovative soft - tissue reconstruction solutions that optimize clinical outcomes by prioritizing the Preservation and Restoration of the patient’s own anatomy. 3 Our Mission
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Reiterates 2024 Revenue Guidance and Expects
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
We provide innovative soft - tissue reconstruction solutions that optimize clinical outcomes by prioritizing the Preservation and Restoration of the patient’s own anatomy. Our Mission 3
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Results and Reiterates Full Year 2024 Revenue Guidance
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Leading - edge atraumatic hernia mesh fixation devices
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
MALVERN, Pa., June 4, 2024, (GLOBE NEWSWIRE) -- TELA Bio, Inc.
Executive or director change · Shareholder vote results · Other events · EX-99.1 to Form 8-K
MALVERN, Pa., May 20, 2024 (GLOBE NEWSWIRE) --
Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Leading - edge atraumatic hernia mesh fixation devices
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
IHR – Addressing the Need for a More Natural Repair in Inguinal Hernia Procedures
Other events · EX-99.1 to Form 8-K
Quarter and Full Year 2023 Revenues and Reports Complete Financial Results
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Leading - edge atraumatic hernia mesh fixation devices
Results of operations · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
of LIQUIFIX™ – the Only FDA-Approved Liquid Adhesive for Internal Use in Hernia Surgery
Results of operations · Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
Rights for Wound Care Product to MIMEDX
Other events · EX-99.1 to Form 8-K
MALVERN, PA, November 9, 2023 -- TELA
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
OviTex ® PRS Long-Term Resorbable for Plastic and Reconstructive Surgery
Other events · EX-99.1 to Form 8-K
PA, August 9, 2023 -- TELA Bio, Inc. ("TELA Bio"),
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Bio Reports First Quarter 2023 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
510(k) Clearance for OviTex ® PRS Long-Term Resorbable for Plastic and Reconstructive Surgery
Other events · EX-99.1 to Form 8-K
Fourth Quarter and Full Year 2022 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K